Avemar research history

1940
Hullet and Stern analyzed the chemical changes during the fermentation of wheat germ with yeast.
1960
Nobel laureate Albert Szent-Györgyi, in his Woods Hole laboratory, presumes that the lack of ascorbic acid and methoxy-substituted benzoquinones is related to the development of cancer. His idea was that these compounds also might have primary roles in maintaining immunity.
1990
92:
Máté Hidvégi, professor of biochemistry in Budapest - based on the ideas of Szent-Györgyi - works on the production of a natural-based quinone-concentrate. Rita Tömösközi-Farkas, a student of Hidvégi, who works in the laboratory of Hermann Esterbauer in Graz., joins the research program.
95:
Professors Károly Lapis and Béla Szende, and Dr. Erzsébet Rásó, all from the Semmelweis Medical University of Budapest, find that Hidvégi's extract of wheat germ significantly inhibits, if combined with chemotherapeutic agents prevents malignant tumors from metastasizing. These results are based on research using several thousand animals.
96:
As a result of further animal studies they postulate that the extract's immune-reconstructive properties are primarily responsible for these incredible effects. They also point out that this agent selectively inhibits adhesion, division of cancer cells and increases their apoptosis. The experiments of Dr. László Prónai in Japan show the antioxidant qualities of the extract. Avemar did not prove to be poisonous in toxicological investigations. The experiments are funded by private individuals: Mihály Kupa and Ákos Resetár economists.
97:
Máté Hidvégi, László Nagypál and Klára Dési elaborate the industrial manufacturing technology of the extract. The final steps are developed in Israel.
Biromedicina - Fist Hungarian Corpoartion for Cancer Research and Oncology is founded for the further research and launching of Avemar.
Later, Ákos Resetár, CEO of Biromedicina Group announces acquisition of the frist Hungarian biotech company with GMP drug manufacuring certificate, ISO, Prima Planta (today: Biropharma).
98:
Avemar's professional presentation in Tel Aviv and Budapest. Hungarian Ministry of Health approves the distribution of Avemar as a dietary supplement.
99:
The teams of Dr. Éva Monostori and Prof. Erno Duda, both at the Biological Research Center at Szeged, start to clear up the mechanism by which Avemar works.
2000
00:
Prof. Ferenc Jakab et al., at the university clinics in Budapest, Szeged and Debrecen, find that Avemar in patients with colon and rectal cancer retards up progression of cancer growth including the development of metastases. Prof. Ottó Ribári et al., at the Semmelweis Medical University, experience beneficial effects of the preparation in patients with head and neck cancer. Prof. Ádám Balogh et al., at Szeged Medical University, find that Avemar considerably reduces the side effects of chemotherapy. The latter is reaffirmed by experiments of Prof. Julia Gidáli et al. at the National Institute of Hematology and Immunology in Budapest. Prof. Géza Bálint et al. at the National Center of Rheumatology in Budapest, show that the product is clinically efficient in rheumatoid arthritis. Prof. György Falkay et al. at the Szeged Medical University, demonstrate the general anti-inflammatory effect of Avemar. Prof. Attila Zalatnai et al. at the Semmelweis Medical University, prove the ability of the preparation to prevent cancer. Prof. Yehuda Shoenfeld et al. at Tel Aviv University show the effectiveness of the product in SLE. Prof. László Boros et al. at UCLA realize that Avemar inhibits the division of cancer cells by a mechanism independent of the immune system.
01:
Prof. Anna Tompa et al. in Budapest, show that Avemar is able to improve the immune system also in patients not having cancer. Schoenfeld's team realizes that Avemar also inhibits autoimmune atherosclerosis. Prof. Lev Demidov et al. at the Blohin Oncology Institute in Moscow, find that Avemar strongly inhibits the development of metastases in patients with melanoma. Professors Ferenc Jakab, Ádám Balogh and Péter Sápy prove that Avemar not only holds up progression, but significantly prolongs survival in advanced colon and rectal cancer. Dr. Zoltán Ajkay et al. at the National Institute of Pulmonology in Budapest, show that the preparation considerably improves quality of life for patients afflicted by advanced lung cancer. Dr. Éva Monostori, Prof. Erno Duda, Dr. Endre Kiss-Tóth and Prof. Steven Dower from the University of Sheffield publish Avemar's hypothetical mechanism of action. Based on comparative laboratory studies of Avemar and anti-cancer drugs, Prof. Marta Cascante at Barcelona University and Prof. László Boros at UCLA presume that Avemar also might be of use for treating stage IV. cancer patients. By synthesis of the results Dr. András Telekes at the National Institute of Oncology in Budapest, outlines Avemar's complex mechanism of action.
02:
Avemar is registered in Hungary with an authority approved label as a "medical nutriment for cancer patients". CNN comments the event as "cancer reserch in Hungary has reached a turning point".
Lajos Koltai, Academy Award-Winner cameraman makes the first television advertisement for the Avemar Project. Faces of the Italian Renessaince take part in the communication to medical professionals.
03:
Avemar gets approved label with cancer claims in the Czech Republic and in Bulgaria. At this time Avemar is available in 10 markets around the world.
"A medical nutriment has supportive value in the treatment of colorectal cancer." - First time clinical data of a medical nutriment are published in British Journal of Cancer.
04:
Launching of www.avemar.com.